SRL
GALT icon

Scientech Research LLC’s Galectin Therapeutics GALT Stock Holding History

Scientech Research LLC’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,346
Closed -$17.2K – 658
2024
Q4 		$17.2K Buy
+13,346
New +$32K ﹤0.01% 536

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Scientech Research LLC's GALT Position: Q1 2025 in Review

Scientech Research LLC sold out of Galectin Therapeutics (GALT) in Q1 2025, closing a stake of 13,346 shares — an estimated $17.2K sold.

Scientech Research LLC first reported a position in GALT in Q4 2024 and held it in 1 quarter. The position peaked at $17.2K in Q4 2024. 93 funds tracked by Wall St. Rank hold GALT as of Q1 2025.

  • Scientech Research LLC reported no remaining Galectin Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Scientech Research LLC sold 13,346 Galectin Therapeutics shares in Q1 2025, an estimated $17.2K.
  • Scientech Research LLC first reported a position in Galectin Therapeutics in Q4 2024 and held it in 1 quarter.
  • Scientech Research LLC's Galectin Therapeutics position peaked at $17.2K in Q4 2024.
  • 93 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2025.

Based on Scientech Research LLC's 13F filing for Q1 2025, filed 15 May 2025.